Kintara Therapeutics Inc
(NASDAQ:KTRA)
$6.20
-0.48[-7.19%]
At close: Feb 8
$6.61
0.4100[6.61%]
After Hours: 9:23AM EDT
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kintara Therapeutics Stock (NASDAQ:KTRA), Quotes and News Summary

Kintara Therapeutics Stock (NASDAQ: KTRA) stock price, news, charts, stock research, profile.

Loading...
Day Range6.200 - 6.94052 Wk Range3.502 - 42.000Open / Close6.560 / 6.430Float / Outstanding1.608M / 1.616M
Vol / Avg.17.123K / 385.332KMkt Cap10.020MP/E-50d Avg. Price7.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float1.608MEPS-17.000
Adam Eckert - Nov 28, 2022, 9:30AM
InvestorsObserver - Dec 2, 2022, 5:56AM
Seeking Alpha - Nov 28, 2022, 12:38PM
InvestorsObserver - Oct 19, 2022, 1:47PM
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The Company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Earnings

see more
Q2 2023Est.ActualSurprise
EPS
(EXPECTED)2023-02-21
REV
Q1 2023Est.ActualSurprise
EPS-3.500
REV4.710M0-4.710M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) competitors?

Q

What is the target price for Kintara Therapeutics (KTRA) stock?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on Thursday, September 29, 2022. The analyst firm set a price target for 0.00 expecting KTRA to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kintara Therapeutics (KTRA)?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $6.2 last updated February 8, 2023 at 8:51 PM UTC.

Q

Does Kintara Therapeutics (KTRA) pay a dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A

Kintara Therapeutics’s Q2 earnings are confirmed for Tuesday, February 21, 2023.

Q

Is Kintara Therapeutics (KTRA) going to split?

A

There is no upcoming split for Kintara Therapeutics.

Q

What sector and industry does Kintara Therapeutics (KTRA) operate in?

A

Kintara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.